XHKG2216
Market cap40mUSD
Dec 23, Last price
0.59HKD
1D
3.51%
1Q
20.41%
IPO
-95.99%
Name
Broncus Holding Corp
Chart & Performance
Profile
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | 10,255 8.95% | 9,413 -13.57% | 10,891 234.18% | ||
Cost of revenue | 43,597 | 41,683 | 50,160 | ||
Unusual Expense (Income) | |||||
NOPBT | (33,342) | (32,270) | (39,269) | ||
NOPBT Margin | |||||
Operating Taxes | 3 | 3 | 3 | ||
Tax Rate | |||||
NOPAT | (33,345) | (32,273) | (39,272) | ||
Net income | (28,091) 0.20% | (28,036) -88.13% | (236,178) 384.11% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 55 | 119 | 214,899 | ||
BB yield | -0.01% | -0.01% | -8.92% | ||
Debt | |||||
Debt current | 1,131 | 681 | 752 | ||
Long-term debt | 3,563 | 2,232 | 3,131 | ||
Deferred revenue | 53 | 102 | 28 | ||
Other long-term liabilities | 175 | 200 | |||
Net debt | (88,223) | (111,446) | (223,324) | ||
Cash flow | |||||
Cash from operating activities | (26,132) | (30,954) | (31,494) | ||
CAPEX | (664) | (856) | (1,881) | ||
Cash from investing activities | 5,486 | (87,569) | (1,753) | ||
Cash from financing activities | (1,459) | (572) | 241,822 | ||
FCF | (33,930) | (37,926) | (41,059) | ||
Balance | |||||
Cash | 156,884 | 187,909 | 227,207 | ||
Long term investments | (63,967) | (73,550) | |||
Excess cash | 92,404 | 113,888 | 226,662 | ||
Stockholders' equity | (461,887) | (379,976) | (349,601) | ||
Invested Capital | 649,665 | 594,861 | 594,090 | ||
ROIC | |||||
ROCE | |||||
EV | |||||
Common stock shares outstanding | 488,571 | 487,749 | 298,960 | ||
Price | 0.79 -65.50% | 2.29 -71.59% | 8.06 | ||
Market cap | 385,971 -65.44% | 1,116,946 -53.65% | 2,409,621 | ||
EV | 297,747 | 1,005,500 | 2,186,297 | ||
EBITDA | (30,476) | (29,422) | (36,578) | ||
EV/EBITDA | |||||
Interest | 163 | 98 | 170 | ||
Interest/NOPBT |